MXB 009
Alternative Names: MXB-009; MXB-9Latest Information Update: 08 Apr 2021
At a glance
- Originator Maxwell Biosciences
- Developer Maxwell Biosciences; Stanford University; University of Louisville; University of Otago
- Class Antimicrobial cationic peptides; Antivirals; Peptoids; Small molecules
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Herpes labialis
Most Recent Events
- 08 Apr 2021 Maxwell Biosciences has patent protection for composition of matter for its anti-infectives program (Maxwell Biosciences pipeline, April 2021)
- 08 Apr 2021 Maxwell Biosciences has patent protection for virucidal peptoid class in USA (Maxwell Biosciences pipeline, April 2021)
- 05 Apr 2021 Preclinical trials in COVID-2019 infections in New Zealand (unspecified route) (Maxwell Bioscien)ces pipeline April 2021